4 citations
,
November 2022 in “Frontiers in Immunology” Lung and liver macrophages protect our tissues and their dysfunction can cause various diseases.
4 citations
,
October 2022 in “Genes” Our microbiome may affect the development of the hair loss condition Alopecia Areata, but more research is needed to understand this relationship.
3 citations
,
January 2025 in “Burns & Trauma” Glucose metabolism is crucial for wound healing but can delay healing in chronic wounds due to increased stress and inflammation.
3 citations
,
April 2022 in “Biomolecules” Higher miR-34a levels and the A variant of the MIR-34A gene are linked to increased risk and severity of alopecia areata.
2 citations
,
September 2025 in “Journal of Clinical Medicine” Small extracellular vesicles can help diagnose and manage sepsis.
2 citations
,
January 2025 in “International Journal of Molecular Sciences” Chitosan-encapsulated Cordyceps militaris reduces lung cell damage from pollution.
2 citations
,
July 2024 in “Indian Journal of Dermatology Venereology and Leprology” Children with atopic diseases have a higher risk of developing alopecia areata.
2 citations
,
December 2024 in “Neural Regeneration Research” Exosome therapy could revolutionize stroke treatment, but more research is needed for human use.
1 citations
,
February 2025 in “Medicina” No significant genetic link to alopecia areata was found in the Jordanian group.
1 citations
,
April 2024 in “Cells” Corneal cells can potentially revert to stem cells, aiding in repair and regeneration.
1 citations
,
December 2023 in “Biomolecules” Regulating cell death in hair follicles can help prevent hair loss and promote hair growth.
January 2025 in “Journal of Personalized Medicine” People with Alopecia Areata are more likely to have prediabetes and obesity.
March 2026 in “Cell Death Discovery” Targeting the p63 gene could help treat skin diseases.
July 2025 in “Russian Journal of Clinical Dermatology and Venereology” Alopecia areata in children requires thorough diagnosis and treatment due to its impact on quality of life and link to other autoimmune diseases.
January 2023 in “Karger Kompass. Dermatologie” Scientists are still unsure what triggers the immune system to attack hair follicles in Alopecia areata.
1 citations
,
March 2025 in “Molecular Medicine Reports” Exosomes show promise in treating acute kidney injury by protecting and repairing kidney cells.
March 2025 in “Archives of Dermatological Research” miR-155-5p can help diagnose and track alopecia areata severity.
September 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” New RIPK4 gene mutations were found to cause a type of skin and limb birth defect.
July 2025 in “Journal of Investigative Dermatology” Resident memory T cells and necroptosis may drive fibrosis in eosinophilic fasciitis and morphea.
Blocking CXCR4 may help treat hidradenitis suppurativa.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
6 citations
,
November 2023 in “Clinical Pharmacokinetics” Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
June 2025 in “British Journal of Dermatology” Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.
December 2025 in “The Journal of Dermatology” Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.
5 citations
,
February 2025 in “Pediatric Dermatology” Ritlecitinib was generally well tolerated in children with alopecia areata.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
December 2025 in “International Journal of Innovative Technologies in Social Science” Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
5 citations
,
February 2024 in “Clinical Pharmacokinetics” A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
December 2023 in “Journal of Ayub Medical College Abbottabad” Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
84 citations
,
August 2023 in “Drugs” Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.